Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 8

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 8
---
 prospectus supplement, the attached prospectus and the documents incorporated by reference herein or therein, is accurate as of any date other than the date on the front of these documents. Our business, financial condition, results of operations and prospects may have changed since that date.

S-5

SUMMARY

This summary does not contain all of the information that may be important to you. You should read carefully the entire prospectus supplement, the attached prospectus and the additional documents incorporated by reference herein for more information about us.

Overview

We are a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of
therapeutic solutions. In 2024, our net sales amounted to €41,081 million. Sanofi is the parent of a consolidated group of companies. We have one operating segment: Biopharma. It comprises commercial operations and research, development
and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories. Sanofi’s activities are organized around the following categories:
DUPIXENT, Neurology & Immunology, Rare Diseases, Oncology, Rare Blood Disorders, General Medicines Core Assets and Non-Core Assets and Vaccines.

Acquisitions

On July 17, 2025,
Sanofi completed its acquisition of Blueprint Medicines Corporation (“Blueprint”), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (“SM”), a rare immunological disease, and other KIT-driven diseases. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline.
Furthermore, Blueprint’s established presence among allergists, dermatologists, and immunologists is expected to improve Sanofi’s ability to enhance its growing immunology pipeline. The acquisition also includes elenestinib, a
next-generation medicine for SM, as well as BLU-808, a highly potent and selective oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Under the terms of the
acquisition, Sanofi paid $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion for 100% of the shares. Blueprint shareholders also received one non-tradeable and
non-transferable contractual contingent value right (“CVR”) per share which entitles the